185 related articles for article (PubMed ID: 29554464)
1. Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.
Munoz DF; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):32S-43S. PubMed ID: 29554464
[TBL] [Abstract][Full Text] [Related]
2. A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.
Munoz DF; Xu C; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):89S-98S. PubMed ID: 29554473
[TBL] [Abstract][Full Text] [Related]
3. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.
Plevritis SK; Munoz D; Kurian AW; Stout NK; Alagoz O; Near AM; Lee SJ; van den Broek JJ; Huang X; Schechter CB; Sprague BL; Song J; de Koning HJ; Trentham-Dietz A; van Ravesteyn NT; Gangnon R; Chandler Y; Li Y; Xu C; Ergun MA; Huang H; Berry DA; Mandelblatt JS
JAMA; 2018 Jan; 319(2):154-164. PubMed ID: 29318276
[TBL] [Abstract][Full Text] [Related]
4. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.
Munoz D; Near AM; van Ravesteyn NT; Lee SJ; Schechter CB; Alagoz O; Berry DA; Burnside ES; Chang Y; Chisholm G; de Koning HJ; Ali Ergun M; Heijnsdijk EA; Huang H; Stout NK; Sprague BL; Trentham-Dietz A; Mandelblatt JS; Plevritis SK
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255803
[TBL] [Abstract][Full Text] [Related]
5. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
[TBL] [Abstract][Full Text] [Related]
6. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian Simulation Model for Breast Cancer Screening, Incidence, Treatment, and Mortality.
Huang X; Li Y; Song J; Berry DA
Med Decis Making; 2018 Apr; 38(1_suppl):78S-88S. PubMed ID: 28627297
[TBL] [Abstract][Full Text] [Related]
8. Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.
Orucevic A; Chen J; McLoughlin JM; Heidel RE; Panella T; Bell J
Breast J; 2015; 21(2):147-54. PubMed ID: 25600504
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
10. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
11. Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.
Mandelblatt JS; Near AM; Miglioretti DL; Munoz D; Sprague BL; Trentham-Dietz A; Gangnon R; Kurian AW; Weedon-Fekjaer H; Cronin KA; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):9S-23S. PubMed ID: 29554466
[TBL] [Abstract][Full Text] [Related]
12. A simulation model investigating the impact of tumor volume doubling time and mammographic tumor detectability on screening outcomes in women aged 40-49 years.
Bailey SL; Sigal BM; Plevritis SK
J Natl Cancer Inst; 2010 Aug; 102(16):1263-71. PubMed ID: 20664027
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
14. The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update.
Alagoz O; Ergun MA; Cevik M; Sprague BL; Fryback DG; Gangnon RE; Hampton JM; Stout NK; Trentham-Dietz A
Med Decis Making; 2018 Apr; 38(1_suppl):99S-111S. PubMed ID: 29554470
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
16. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
17. Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.
van den Broek JJ; van Ravesteyn NT; Heijnsdijk EA; de Koning HJ
Med Decis Making; 2018 Apr; 38(1_suppl):54S-65S. PubMed ID: 29554469
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
19. Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.
Schechter CB; Near AM; Jayasekera J; Chandler Y; Mandelblatt JS
Med Decis Making; 2018 Apr; 38(1_suppl):66S-77S. PubMed ID: 29554462
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Breast Cancer Mortality in the US-1975 to 2019.
Caswell-Jin JL; Sun LP; Munoz D; Lu Y; Li Y; Huang H; Hampton JM; Song J; Jayasekera J; Schechter C; Alagoz O; Stout NK; Trentham-Dietz A; Lee SJ; Huang X; Mandelblatt JS; Berry DA; Kurian AW; Plevritis SK
JAMA; 2024 Jan; 331(3):233-241. PubMed ID: 38227031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
